Archer Investment Corporation’s BioMarin Pharmaceuticals BMRN Stock Holding History

Archer Investment Corporation’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.95K	Hold	70	–	–	﹤0.01%	962
2025 Q4	$4.16K	Hold	70	–	–	﹤0.01%	896
2025 Q3	$3.79K	Hold	70	–	–	﹤0.01%	904
2025 Q2	$3.85K	Hold	70	–	–	﹤0.01%	883
2025 Q1	$4.95K	Hold	70	–	–	﹤0.01%	821
2024 Q4	$4.6K	Hold	70	–	–	﹤0.01%	835
2024 Q3	$4.92K	Hold	70	–	–	﹤0.01%	812
2024 Q2	$5.76K	Hold	70	–	–	﹤0.01%	759
2024 Q1	$6.11K	Hold	70	–	–	﹤0.01%	738
2023 Q4	$6.75K	Hold	70	–	–	﹤0.01%	722
2023 Q3	$6.19K	Hold	70	–	–	﹤0.01%	713
2023 Q2	$6.07K	Buy	+70	New	+$6.59K	﹤0.01%	712

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Archer Investment Corporation's BMRN Position: Q1 2026 in Review

Archer Investment Corporation held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2026 at 70 shares worth $3.95K. The position accounts for ﹤0.01% of the portfolio, ranked #962.

Archer Investment Corporation first reported a position in BMRN in Q2 2023 and has held it in 12 quarters since. The position peaked at $6.75K in Q4 2023. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Archer Investment Corporation held 70 shares of BioMarin Pharmaceuticals worth $3.95K as of Q1 2026.
Archer Investment Corporation left its BioMarin Pharmaceuticals share count unchanged in Q1 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Archer Investment Corporation's portfolio in Q1 2026, its #962 holding.
Archer Investment Corporation first reported a position in BioMarin Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Archer Investment Corporation's BioMarin Pharmaceuticals position peaked at $6.75K in Q4 2023.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Archer Investment Corporation's 13F filing for Q1 2026, filed 4 May 2026.